nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

6. Therapieplanung

verfasst von : Dr. med. Jost von Hardenberg, PD Dr. med. Manuel Ritter, Prof. Dr. med. Frederik Wenz, Dr. med. Ali Abaci

Erschienen in: MR- und PET-Bildgebung der Prostata

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die fokale HIFU-Therapie stellt einen experimentellen kurativen Therapieansatz dar und kommt für Patienten mit einem niedrig bis früh-intermediären Risikoprostatakarzinom oder einem Rezidiv nach externer Radiatio in Betracht. Im Vordergrund für die Therapieplanung steht die korrekte Identifikation des Indextumors sowie dessen Ausdehnung für die gezielte Biopsie. Entspricht der Gleason Score den Kriterien für die fokale HIFU-Therapie, kann die Behandlung anhand des mpMRT geplant werden. Die radikale Prostatektomie stellt die häufigste primäre Therapieoption im lokal begrenzten und fortgeschrittenen Prostatakarzinom dar. Angesichts der guten Korrelation zwischen dem mpMRT und Großflächenschnitten der Prostata bietet sich eine Nutzung für die Therapieplanung an. Die Radiotherapie wird in kurativer Intention ebenfalls als primäre Therapieoption eingesetzt. Weiterhin kann sie adjuvant bei entsprechender Risikokonstellation früh postoperativ in kurativer Intention erfolgen. Auch beim PSA-Rezidiv nach einer radikalen Prostatektomie steht die Salvage-Radiotherapie als kurative Therapie zur Verfügung und kann mit einer antihormoneller Behandlung kombiniert werden.

Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Briganti A (2014). Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol, 65(3):554–562. doi: 10.1016/j.eururo.2013.09.025

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Prostatakarzinoms, Langversion 3.1. AWMF-Registernummer: 034/022OL. 2014

Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, Palmer S, Matsugasumi T, Marien A, Bernhard JC, Rewcastle JC, Eggesbø HB, Gill IS (2014) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794

Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Bolla M (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology 79(3):259–269. doi: 10.1016/j.radonc.2006.05.012

Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Collette L (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi: 10.1056/NEJMoa0810095

Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, De Reijke TM, Genito-Urinary G (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 380(9858):2018-2027. doi: 10.1016/S0140-6736(12)61253–1257

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Collette L (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol, 11(11):1066–1073. doi: 10.1016/s1470-2045(10)70223-0

Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Blute M (2011) Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59(5):832–840. doi: 10.1016/j.eururo.2011.02.024

Collette L, Van Poppel H, Bolla M, Van Cangh P, Vekemans K, Da Pozzo L, Piérart M (2005) Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). European Journal of Cancer 41(17):2662–2672. doi: http://dx.doi.org/10.1016/j.ejetwa2005.06.024

De Carlo F, Celestino F, Verri C, Masedu F, Liberati E, Di Stasi SM (2014) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review. Urologia internationalis 93(4):373–383

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL (2015) Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. The Journal of urology 194(2):343–349

Dubbelman YD, Dohle GR, Schröder FH (2006) Sexual function before and after radical retropubic prostatectomy: A systematic review of prognostic indicators for a successful outcome. European urology 50(4):711–718; discussion 718–720

Edamura K, Saika T, Senoh T, Koizumi F, Manabe D, Ebara S, Kumon H (2005) Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. Acta Med Okayama 59(5):195–199

Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA, Sala E, Hricak H, Deasy JO (2015) Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proceedings of the National Academy of Sciences of the United States of America 112(46):E6265–6273

Finley DS, Margolis D, Raman SS, Ellingson BM, Natarajan S, Tan N, Huang J, Reiter RE (2013) Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urologic oncology 31(6):766–775

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Langley S (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int, 109 Suppl 1, 22-29. doi: 10.1111/j.1464-410X.2011.10827.x

Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46(4):823–832

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61-71. doi: 10.1016/j.eururo.2010.10.039

Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP (2016) ⁶⁸Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol doi:10.1016/j.eururo.2015.12.051. [epub ahead of print]

Hiddemann W, Bartram CR (2004) Die Onkologie. Springer-Verlag Berlin Heidelberg New York

Hollmann BG, Van Triest B, Ghobadi G, Groenendaal G, De Jong J, Van der Poel HG, Van der Heide UA (2015) Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion. Radiotherapy and oncology? J European Society for Therapeutic Radiology and Oncology 115(1):96–100

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74. doi: 10.1016/j.ijrobp.2007.06.054

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Klein EA (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58(1):25–33

Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Thomas CR Jr (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655. doi: 10.1016/j.ijrobp.2007.04.003

Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJA, Raman SS, Reiter RE (2014) Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. Eur Urol 67(3):569–576

Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason Score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095–1101

Matikainen MP, Von Bodman CJ, Secin FP, Yunis LH, Vora K, Guillonneau B, Laudone V, Eastham JA, Scardino PT, Akin O, Rabbani F (2010) The depth of the prostatic apex is an independent predictor of positive apical margins at radical prostatectomy. BJU international 106(5):622–666

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M (2015) Diagnostic efficacy of (68)Gallium-PSMA-PET compared to conventional imaging in lymph node staging of of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol 195(5):1436–1443

Nix, J. W, Turkbey, B, Hoang, A, Volkin, D, Yerram, N, Chua, C, Linehan, W. M, Wood, B, Choyke, P, Pinto, P. A. Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU international 2012;110(11 Pt B):E694–700

Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, Shariat SF, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG (2012) Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. European urology 62(3):431–452

Petralia G, Musi G, Padhani AR, Summers P, Renne G, Alessi S, Raimondi S, Matei DV, Renne SL, Jereczek-Fossa BA, De Cobelli O, Bellomi M (2015) Robot-assisted radical prostatectomy: Multiparametric MR imaging-directed intraoperative frozen-section analysis to reduce the rate of positive surgical margins. Radiology 274(2):434–444

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys, 53(5):1097–1105

Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Bolla M (2007) Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84(2):121–127. doi: 10.1016/j.radonc.2007.07.017

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281(17):1591–1597

Prostate cancer: large PREFERE Study evaluates therapies (2013) Aktuelle Urol 44(2):105. doi: 10.1055/s-0033-1343926

Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, Popeneciu IV, Huettenbrink C, Gasch C, Klein T, Bonekamp D, Duensing S, Roth W, Schueler S, Stock C, Schlemmer HP, Roethke M, Hohenfellner M, Hadaschik BA (2016) Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol 2016 Jan 19. doi:10.1016/j.eururo.2015.12.052 [epub ahead of print]

Ream JM, Glielmi C, Lazar M, Campbell N, Pfeuffer J, Schneider R, Rosenkrantz AB (2016) Zoomed echo-planar diffusion tensor imaging for MR tractography of the prostate gland neurovascular bundle without an endorectal coil: a feasibility study. Abdominal Radiology 41(5):919–925

Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M (2013) Hybrid Positron Emission Tomography – Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer – Preliminary Results. European Urology 64(5):862–864

Rud E, Baco E, Lien D, Klotz D, Eggesbø HB (2014a) Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies. AJR. American journal of roentgenology 202(3):W241–246

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbø HB (2014b) Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone. BJU international 114(6b):E32–42

Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N (2006) Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. Asian J Androl 8(5):555–561. doi: 10.1111/j.1745-7262.2006.00175.x

Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, Heinzer H, Hansen J, Budäus L, Steurer S, Wittmer C, Minner S, Haese A, Sauter G, Graefen M, Huland H (2012) Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. European urology 62(2):333–340

Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, Littrup PJ (1999) Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 54(6):1044–1048

Shelan M, Abo-Madyan Y, Welzel G, Bolenz C, Kosakowski J, Behnam N, Lohr F (2013) Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol 8:276. doi: 10.1186/1748-717X-8-276

Sivaraman A, Barret E (2016) Focal Therapy for Prostate Cancer: An »À la Carte« Approach. Eur Urol doi:10.1016/j.eururo.2015.12.051. [epub ahead of print]

Somford DM, Hamoen EH, Fütterer JJ, Van Basten JP, Hulsbergen-Van de Kaa CA, Vreuls W, Van Oort IM, Vergunst H, Kiemeney LA, Barentsz JO, Witjes JA (2013) The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. The Journal of urology 190(5):1728–1734

Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Rabah DM, Eastham JA, Scardino PT (2014) Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. European urology 65(4):675–680

Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24(24):3973–3978. doi: 10.1200/JCO.2005.04.0756

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Pollack A (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol, 25(15):2035–2041. doi: 10.1200/jco.2006.08.9607

Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA, Carver BS (2009) Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 182(4):1357–1363. doi: 10.1016/j.juro.2009.06.046

Van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, De la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT (2014) Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. European urology 65(6):1078–1083

Van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B (2011) International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern pathology? An official journal of the United States and Canadian Academy of Pathology Inc 24(1):16–25

Van der Kwast TH, Collette L, Bolla M (2007) Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J Clin Oncol 25(35):5671–5672. doi: 10.1200/JCO.2007.14.2018

Weidner AM, Michaely HJ, Lemke A, Breitinger L, Wenz F, Marx A, Dinter DJ (2011) Value of multiparametric prostate MRI of the peripheral zone. Z Med Phys 21(3):198–205. doi: 10.1016/j.zemedi.2010.12.004

Weidner AM, Van Lin EN, Dinter DJ, Rozema T, Schoenberg SO, Wenz F, Lohr F (2011) Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse. Strahlenther Onkol, 187(3):206–212. doi: 10.1007/s00066-010-2195-1

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Fossa SD (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet, 373(9660):301–308. doi: 10.1016/s0140-6736(08)61815–61822

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Miller K (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66(2):243–250. doi: 10.1016/j.eururo.2014.03.011

Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60(2):264–269

Yeboah C, Sandison GA (2002) Optimized treatment planning for prostate cancer comparing IMPT, VHEET and 15 MV IMXT. Phys Med Biol, 47(13):2247–2261

Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Zhang Z (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol, 60(6):1133–1139. doi: 10.1016/j.eururo.2011.08.029

Titel: Therapieplanung
verfasst von: Dr. med. Jost von Hardenberg
PD Dr. med. Manuel Ritter
Prof. Dr. med. Frederik Wenz
Dr. med. Ali Abaci
Verlag: Springer Berlin Heidelberg
Buch: MR- und PET-Bildgebung der Prostata
Print ISBN: 978-3-662-50467-3

Electronic ISBN: 978-3-662-50468-0

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-50468-0_6

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

6. Therapieplanung

Zusammenfassung

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie